Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Acorda Therapeutics Inc chart...

About the Company

acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate

CEO

Ron Cohen

Exchange

NASDAQ

Website

http://www.acorda.com/

$123M

Total Revenue

344

Employees

$17M

Market Capitalization

-0.78

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACOR News

Acorda Therapeutics Inc ACOR

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Acorda Stock Gaps Up On Today's Open (ACOR)

12y ago, source: TheStreet.com

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders.

Acorda Therapeutics files patent for dry powder lung surfactant formulation for inhalation delivery

6d ago, source: Pharmaceutical Technology

Discover Acorda Therapeutics' innovative patent for a dry powder lung surfactant formulation, revolutionizing pulmonary drug delivery for patients with respiratory ailments.

Acorda Therapeutics Inc ACOR

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Acorda Therapeutics, Inc. (ACOR)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Acorda Therapeutics, Inc. Common Stock (ACOR)

9y ago, source: Nasdaq

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

Acorda Therapeutics Inc.

1mon ago, source: MarketWatch

Repurchase of Common & Preferred Stk. Repurchase of Common & Preferred Stk.

Acorda Therapeutics, Inc. Common Stock (ACOR)

4y ago, source: Nasdaq

Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally ...

Acorda Therapeutics, Inc. (ACOR)

1mon ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Acorda Therapeutics, Inc. (ACOR)

6y ago, source: Yahoo Finance

Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53... Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...